



## Trends Shaping the Future of CGT Manufacturing




### Cell and Gene Therapy (CGT) Manufacturing Landscape


The rising incidence of cancer, metabolic and chronic diseases, advancements in exponential technologies, and increasing R&D spending by pharmaceutical companies are fueling significant interest and growth in the CGT market.




### Technologies Powering the Future of CGT Manufacturing




### Decentralized Manufacturing Strategies for CGTs




### Automation of CGT Manufacturing



### Innovations in Single-use Technologies (SUTs)



### Player Perspective: Cell & Gene Therapy Manufacturing



### Conclusion

- CGT Manufacturing Challenges:** Scaling-up operations, high cost of processes and raw materials, product reproducibility during manufacturing
- CDMO Dependence Challenges:** Increased reliance on CDMOs, potential for extended waiting times due to high CGT demand
- Key Considerations for CGT Decision Makers:**
  - Outsourcing preferences and practices and challenges in selecting the right solution providers
  - Selecting the right solution providers is crucial for effectively managing CGT manufacturing challenges, including scaling-up, cost optimization, and reproducibility, and also for meeting the growing demand for CGTs in the future.

### About FutureBridge

FutureBridge tracks and advises on the future of industries from a 1-to-25 year perspective.

We keep you ahead on the technology curve, propel your growth, identify new opportunities, markets and business models, answer your unknowns, and facilitate best-fit solutions and partnerships using our platforms, programs, and access to global ecosystems and players.